絞り込み

16311

広告

Discriminatory power of the 111-indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-yttrium ibritumomab tiuxetan therapeutic regimen: Meta-analysis of five clinical trials and 9 years of post-approval safety data.

著者 Kylstra JW , Witzig TE , Huang M , Emmanouilides CE , Hagenbeek A , Tidmarsh GF
J Clin Oncol.2011 May 20 ; 29(15_suppl):8048.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (15view , 0users)
  • このエントリーをはてなブックマークに追加
8048 Background: At the time of regulatory approval of 90-Y ibritumomab tiuxetan (Zevalin Z), 3 countries (USA, Switzerland, Japan) required labeling specifying that a 111-In imaging scan be performed 7-9 days before the therapeutic 90-Y Z dose, to guard against that the hypothetical risk that altered biodistribution (AB) of the radio-immunoconjugate cause unintended end organ damage; 42 other countries (incl. EU, Canada) approved Z without requiring 111-In.
PMID: 28023566 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード